Combination chemotherapy with etoposide, cisplatin, and doxorubicin in mixed müllerian tumors of the adnexa

I. Cass, E. Resnik, J. T. Chambers, S. K. Chambers, M. L. Carcangiu, E. I. Kohorn, P. E. Schwartz

Research output: Contribution to journalArticle

Abstract

Eleven patients with ovarian (9) or fallopian tube (2) mixed müllerian tumors who underwent primary surgery at Yale New Haven Medical Center between 1986 and 1994 were treated with etoposide, cisplatin, and doxorubicin. Responses were observed in three (60%) of five evaluable patients with two complete (40%) and one partial (20%) response. Median survival time was 17 months with an estimated 3-year survival of 18%. Survival may have been improved with earlier stage disease, but survival was not significantly improved with optimal surgical cytoreduction in patients with advanced disease. Four patients required dose reductions for myelosuppression and there was one treatment related death. Toxicity was comparable to other combination chemotherapy regimens. EPA has modest therapeutic activity in ovarian and fallopian tube MMT.

Original languageEnglish
Pages (from-to)309-314
Number of pages6
JournalGynecologic Oncology
Volume61
Issue number3
DOIs
Publication statusPublished - Jun 1996

ASJC Scopus subject areas

  • Obstetrics and Gynaecology
  • Oncology

Fingerprint Dive into the research topics of 'Combination chemotherapy with etoposide, cisplatin, and doxorubicin in mixed müllerian tumors of the adnexa'. Together they form a unique fingerprint.

  • Cite this

    Cass, I., Resnik, E., Chambers, J. T., Chambers, S. K., Carcangiu, M. L., Kohorn, E. I., & Schwartz, P. E. (1996). Combination chemotherapy with etoposide, cisplatin, and doxorubicin in mixed müllerian tumors of the adnexa. Gynecologic Oncology, 61(3), 309-314. https://doi.org/10.1006/gyno.1996.0148